KSE - Delayed Quote KRW

JW Lifescience Corporation (234080.KS)

Compare
11,310.00 +10.00 (+0.09%)
At close: 3:30 PM GMT+9
Loading Chart for 234080.KS
DELL
  • Previous Close 11,300.00
  • Open 11,310.00
  • Bid 11,310.00 x --
  • Ask 11,740.00 x --
  • Day's Range 11,230.00 - 11,410.00
  • 52 Week Range 10,750.00 - 13,550.00
  • Volume 18,757
  • Avg. Volume 39,617
  • Market Cap (intraday) 175.131B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield 500.00 (4.42%)
  • Ex-Dividend Date Dec 27, 2023
  • 1y Target Est --

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

www.jw-lifescience.co.kr

301

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 234080.KS

View More

Performance Overview: 234080.KS

Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

234080.KS
12.12%
KOSPI Composite Index
6.51%

1-Year Return

234080.KS
7.44%
KOSPI Composite Index
0.36%

3-Year Return

234080.KS
10.08%
KOSPI Composite Index
16.45%

5-Year Return

234080.KS
30.94%
KOSPI Composite Index
16.80%

Compare To: 234080.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 234080.KS

View More

Valuation Measures

Annual
As of 11/19/2024
  • Market Cap

    174.98B

  • Enterprise Value

    186.80B

  • Trailing P/E

    6.07

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.79

  • Price/Book (mrq)

    1.03

  • Enterprise Value/Revenue

    0.84

  • Enterprise Value/EBITDA

    3.43

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.40%

  • Return on Assets (ttm)

    7.74%

  • Return on Equity (ttm)

    17.20%

  • Revenue (ttm)

    214.51B

  • Net Income Avi to Common (ttm)

    26.61B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    34.53B

  • Total Debt/Equity (mrq)

    28.36%

  • Levered Free Cash Flow (ttm)

    8.88B

Research Analysis: 234080.KS

View More

Company Insights: 234080.KS

Research Reports: 234080.KS

View More

People Also Watch